Document is current
Any future updates will be listed below
-
Authors
Chen, Siqi
Wang, Yingyu
Dang, Jessica
Song, Nuozi
Chen, Xiaoxin https://orcid.org/0000-0003-3092-7010
Wang, Jinhui
Huang, Guo N. https://orcid.org/0000-0002-4335-9123
Brown, Christine E. https://orcid.org/0000-0003-4915-8207
Yu, Jianhua
Weissman, Irving L. https://orcid.org/0000-0002-9077-7467
Rosen, Steven T.
Feng, Mingye https://orcid.org/0000-0002-3334-9917
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA258778, R21CA280317, R01CA255250)
V Foundation for Cancer Research (V2018-012)
Beckman Research Institute, City of Hope (Startup research funding)
California Institute for Regenerative Medicine (EDUC4-12772, TRAN1-14003)
American Heart Association (Postdoctoral fellowship, Transformation and Established Investigator Award)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL138456, R01HL157280)
Leukemia and Lymphoma Society (1364-19)
- License Information
-
More Information
Article History
Received: 11 February 2025
Accepted: 15 April 2025
First Online: 30 April 2025
Competing interests
: S.C., S.T.R., and M.F. filed a US patent 63/431,575, “Compositions Comprising Myeloid Phagocytic Cells Expressing A Chimeric Antigen Receptor”. I.L.W. is a cofounder, director, stockholder in and consultant for Forty Seven (but not Gilead). The remaining authors declare no competing interests.
